Potential Mesothelioma Drug Wins Orphan Status from the European Commission
Cambridge, Mass.-based Verastem hopes to bring to the table a new treatment option for patients with asbestos-caused cancer
Cambridge, Mass.-based Verastem hopes to bring to the table a new treatment option for patients with asbestos-caused cancer
The Asbestos Disease Awareness Organization was unhappy to see its suggested amendments stripped from the Chemical Safety Improvement Act of 2013
A new Phase 2 clinical trial at the Angeles Clinic will study tremelimumab as an immunotherapy treatment for pleural and peritoneal mesothelioma.
Spending on inpatient cancer admissions fell from 64% of total cancer spending in 1987 to 27% in 2001-2005, studies say.
The businessman faces time in prison and a hefty fine for the infractions
Recent research shows that a new delivery method can make chemotherapy more effective for lung cancer and possibly mesothelioma.
A federal grand jury is probing issues involving the city’s Hilton Center
While making way for the new National Broadband Network, it was discovered that communications giant Telstra may have used unqualified individuals to remove asbestos in their pits
Researchers at Flinders University in Australia focus on the latest mesothelioma treatment.
Canada may have stepped aside, but seven countries still block efforts at Rotterdam Convention conference to restrict asbestos shipping worldwide.
An Immunotherapy drug testing well with lung cancer has become a future hope for mesothelioma treatment.
Asbestos was once called a miracle material because of its toughness and fire-resistant properties.
The use of asbestos has been reduced dramatically, but mesothelioma incidence rates still on steady course.
Max Baucus leaving U.S. Senate leaves the mesothelioma and asbestos community without one of its strongest supporters
The chances of developing lung cancer associated with asbestos exposure, asbestosis and smoking are dramatically increased when these three risk factors are combined, and quitting smoking…